{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T19:16:53Z","timestamp":1774379813111,"version":"3.50.1"},"reference-count":53,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["PPA"],"DOI":"10.2147\/ppa.s379065","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T05:15:12Z","timestamp":1670908512000},"page":"3267-3281","source":"Crossref","is-referenced-by-count":2,"title":["Virological Outcomes After Switching to Abacavir\/Lamivudine\/Dolutegravir Combined with Adherence Support in People Living with HIV with Poor Adherence: A Phase IV, Multicentre Randomized Prospective Open Label Study (TriiADD-CTN 286)"],"prefix":"10.2147","volume":"Volume 16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3063-8430","authenticated-orcid":true,"given":"Marina B","family":"Klein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4314-3007","authenticated-orcid":true,"given":"Jim","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0431-4889","authenticated-orcid":true,"given":"David","family":"Ortiz-Paredes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shouao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Walmsley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Martel-Laferri\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4123-3698","authenticated-orcid":true,"given":"Neora","family":"Pick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Conway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Angel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Guy","family":"Baril","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Lebouch\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3069-2875","authenticated-orcid":true,"given":"Darrell HS","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Sandre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Trottier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hansi","family":"Peiris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayamarx","family":"Jayaraman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Singer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,12]]},"reference":[{"key":"ref1","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services; 2013. Available from: https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/adult-adolescent-arv\/guidelines-adult-adolescent-arv.pdf. Accessed December 1, 2022."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1080\/09540120412331291715","volume":"17","author":"Godin","year":"2005","journal-title":"AIDS Care"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/00002030-200203290-00012","volume":"16","author":"Lucas","year":"2002","journal-title":"AIDS"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/00126334-200308010-00009","volume":"33","author":"Tesoriero","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.1007\/s12325-021-01883-8","volume":"38","author":"McComsey","year":"2021","journal-title":"Adv Ther"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e003028","DOI":"10.1136\/bmjopen-2013-003028","volume":"3","author":"Cohen","year":"2013","journal-title":"BMJ Open"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s10461-012-0136-y","volume":"17","author":"Werb","year":"2013","journal-title":"AIDS Behav"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2174\/157016210794088227","volume":"8","author":"Martin","year":"2010","journal-title":"Curr HIV Res"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1080\/09540120500481480","volume":"18","author":"Miller","year":"2006","journal-title":"AIDS Care"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1007\/s10461-011-0112-y","volume":"16","author":"Sumari-de Boer","year":"2012","journal-title":"AIDS Behav"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1089\/apc.2012.0296","volume":"27","author":"Logie","year":"2013","journal-title":"AIDS Patient Care STDS"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s10461-006-9201-8","volume":"11","author":"Remien","year":"2007","journal-title":"AIDS Behav"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s10461-015-1142-7","volume":"20","author":"Magidson","year":"2016","journal-title":"AIDS Behav"},{"key":"ref14","unstructured":"UNAIDS. 90-90-90: treatment for all. Available from: https:\/\/www.unaids.org\/en\/resources\/909090. Accessed November 30, 2022."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1097\/QAD.0b013e32832ba8ec","volume":"23","author":"Gardner","year":"2009","journal-title":"AIDS"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1086\/596482","volume":"48","author":"Parienti","year":"2009","journal-title":"Clin Infect Dis"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s10461-010-9818-5","volume":"15","author":"Raboud","year":"2011","journal-title":"AIDS Behav"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e00650","DOI":"10.1002\/prp2.650","volume":"8","author":"Young","year":"2020","journal-title":"Pharmacol Res Perspect"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12981-018-0204-0","volume":"15","author":"Clay","year":"2018","journal-title":"AIDS Res Ther"},{"key":"ref20","unstructured":"ViiV Healthcare ULC Product monograph: prTRIUMEQ. dolutegravir, abacavir, and lamivudine tablets; 2020. Available from: https:\/\/viivhealthcare.com\/content\/dam\/cf-viiv\/viiv-healthcare\/en_CA\/triumeq.pdf. Accessed November 30, 2022."},{"key":"ref21","unstructured":"Stanford University. HIV drug resistance database. HIVdb program: mutations analysis. Available from: https:\/\/hivdb.stanford.edu\/hivdb\/by-patterns\/. Accessed November 30, 2022."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1086\/503914","volume":"42","author":"Liu","year":"2006","journal-title":"Clin Infect Dis"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1001\/jamainternmed.2013.2152","volume":"173","author":"Gross","year":"2013","journal-title":"JAMA Intern Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1007\/s10461-013-0661-3","volume":"18","author":"Belzer","year":"2014","journal-title":"AIDS Behav"},{"key":"ref25","unstructured":"U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Human immunodeficiency virus-1 infection: developing antiretroviral drugs for treatment. Guidance for Industry; 2015. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/human-immunodeficiency-virus-1-infection-developing-antiretroviral-drugs-treatment. Accessed November 30, 2022."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1002\/(SICI)1099-1255(199611)11:6<619::AID-JAE418>3.0.CO;2-1","volume":"11","author":"Papke","year":"1996","journal-title":"J Appl Econ"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/ije\/dyi312","volume":"35","author":"Greenland","year":"2006","journal-title":"Int J Epidemiol"},{"key":"ref28","first-page":"159","volume":"1","author":"Mayring","year":"2000","journal-title":"Forum Qual Soc Res"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1177\/1049732305276687","volume":"15","author":"Hsieh","year":"2005","journal-title":"Qual Health Res"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/9780470753552.ch4","volume":"22","author":"Fisher","year":"2003","journal-title":"Social Psychol Found Health Illness"},{"key":"ref31","unstructured":"UNAIDS. 2025 AIDS targets 2021 [2022-06-15]. Available from: https:\/\/aidstargets2025.unaids.org\/. Accessed November 30, 2022."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2147\/PPA.S192735","volume":"13","author":"Altice","year":"2019","journal-title":"Patient Prefer Adherence"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1097\/QAI.0000000000000082","volume":"65","author":"Hanna","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/hiv.12562","volume":"19","author":"Young","year":"2018","journal-title":"HIV Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"913","DOI":"10.3851\/IMP1644","volume":"15","author":"Nieuwkerk","year":"2010","journal-title":"Antivir Ther"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","volume":"71","author":"van Wyk","year":"2020","journal-title":"Clin Infect Dis"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1016\/S2352-3018(16)30206-5","volume":"4","author":"Kanters","year":"2017","journal-title":"Lancet HIV"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"S187","DOI":"10.1097\/QAD.0000000000000252","volume":"28","author":"Chaiyachati","year":"2014","journal-title":"Aids"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"e011453","DOI":"10.1136\/bmjopen-2016-011453","volume":"6","author":"Rueda","year":"2016","journal-title":"BMJ Open"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s12160-010-9200-x","volume":"40","author":"Bogart","year":"2010","journal-title":"Ann Behav Med"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1093\/ije\/dyu115","volume":"43","author":"Hr\u00f3bjartsson","year":"2014","journal-title":"Int J Epidemiol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1093\/cid\/cir131","volume":"52","author":"Gandhi","year":"2011","journal-title":"Clin Infect Dis"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1097\/QAD.0b013e328325a4a9","volume":"23","author":"Gandhi","year":"2009","journal-title":"AIDS"},{"key":"ref44","first-page":"20","volume":"1","author":"Haynes","year":"2015","journal-title":"Clin Res Trials"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"e701","DOI":"10.1016\/S2214-109X(20)30541-6","volume":"9","author":"Dron","year":"2021","journal-title":"Lancet Glob Health"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"c1066","DOI":"10.1136\/bmj.c1066","volume":"340","author":"Relton","year":"2010","journal-title":"BMJ"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1214\/08-AOAS187","volume":"2","author":"Rubin","year":"2008","journal-title":"Ann Appl Stat"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1136\/bmj.312.7040.1215","volume":"312","author":"Black","year":"1996","journal-title":"BMJ"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1037\/a0032705","volume":"68","author":"Earnshaw","year":"2013","journal-title":"Am Psychol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12916-014-0142-1","volume":"12","author":"Langebeek","year":"2014","journal-title":"BMC Med"},{"key":"ref52","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services; 2021. Available from: https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/AdultandAdolescentGL.pdf."},{"key":"ref53","first-page":"1","volume":"41","author":"Ward","year":"1992","journal-title":"Morb Mortal Wkly Rep Recomm Rep"}],"container-title":["Patient Preference and Adherence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=86083","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=86083","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T05:15:24Z","timestamp":1670908524000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/virological-outcomes-after-switching-to-abacavirlamivudinedolutegravir-peer-reviewed-fulltext-article-PPA"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":53,"URL":"https:\/\/doi.org\/10.2147\/ppa.s379065","relation":{},"ISSN":["1177-889X"],"issn-type":[{"value":"1177-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12]]}}}